Literature DB >> 8584241

AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells.

P J Middlemiss1, A J Glasky, M P Rathbone, E Werstuik, S Hindley, J Gysbers.   

Abstract

AIT-082 is a novel, metabolically stable, derivative of the purine hypoxanthine. Addition of AIT-082 to cultured PC12 cells enhanced significantly nerve growth factor (NGF)-mediated neurite outgrowth from PC12 cells. These results suggest a cellular mechanism, the enhancement of NGF-action, that might account for the ability of AIT-082 to restore age-induced working memory deficits in mice.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8584241     DOI： 10.1016/0304-3940(95)12029-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  4 in total

Review 1.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  A synthetic analog of verbenachalcone potentiates NGF-induced neurite outgrowth and enhances cell survival in neuronal cell models.

Authors:  Ceiléssia M Clement; Srinivasa R Dandepally; Alfred L Williams; Gordon C Ibeanu
Journal:  Neurosci Lett       Date:  2009-05-07       Impact factor: 3.046

3.  A phase I study of AIT-082 in healthy elderly volunteers.

Authors:  Michael Grundman; Martin Farlow; Guerry Peavy; Hyun T Kim; Edmund Capparelli; Arlan N Schultz; David P Salmon; Steven H Ferris; Richard Mobs; Ronald G Thomas; Kimberly Schafer; Karen Campbell; Ann Marie Hake; Barbara Schoos; Leon J Thal
Journal:  J Mol Neurosci       Date:  2002-06       Impact factor: 3.444

4.  Effects of Neurotrophic Support and Amyloid-Targeted Combined Therapy on Adult Hippocampal Neurogenesis in a Transgenic Model of Alzheimer's Disease.

Authors:  Christopher D Morrone; Lynsie A M Thomason; Mary E Brown; Isabelle Aubert; JoAnne McLaurin
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.